🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

SPRO SPRO

Company Profile ↓
$1.26
-45.22% 1Y
Mkt Cap$71.08M
P/E8.40
P/B1.20
52W High$2.98
52W Low$1.15
Book Value$1.05
EPS (TTM)$0.15

Company Overview

SPRO (SPRO) is a publicly traded company listed on with a market capitalization of $71.08M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 91.1% CAGR over the past five years.

Reasonable Valuation

Trades at an undemanding P/E of 8.4.

Recent Developments

  • Dec 2025 Revenue of $59.62M (+117.6% YoY); net profit $8.57M.
  • Trailing 12 Months Year-on-year growth — revenue +117.6%.
  • 5-Year Trend Long-term compounding — revenue CAGR 91.1%.

Growth & Price Performance

Compounded Sales Growth

5 Years:91.11%
1 Year:117.62%

Stock Price Performance

1 Year:-45.22%
6 Months:-41.12%
3 Months:-47.93%
1 Month:-41.67%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 6% of range
$1.15 $2.98
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)30.62 · Neutral
Price Performance
1M-41.67%
3M-47.93%
6M-41.12%
1Y-45.22%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 91.1% over 5 years.

CONS

  • Trading 57.7% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
8.40
Industry PE
-
Forward P/E est.
4.20
PEG Ratio
-
Book Value
$1.05
Price to Book
1.20
P/S
-
EV/EBITDA
-
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
91.11%
Profit 5Y
-
Revenue (YoY)
117.62%
Earnings (YoY)
-

Profitability & Returns

ROCE
11.92%
ROE
14.52%
ROA
12.44%
Profit Margin
14.38%
Op Margin
12.01%
Gross Margin
-
EPS (Latest Qtr)
$-0.13
EPS (TTM)
$0.15

Balance Sheet & Liquidity

Debt/Equity
4.91
Quick Ratio
-
Current Ratio
7.59
Debt
$2.90M
Total Assets
$59.02M
Current Assets
$57.61M
Working Capital
$58.42M

Ownership

Promoter Holding
22.46%
Chg in Prom Hold
-
FII / Inst Holding
16.22%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
-
Total Revenue (TTM)
$59.62M
EBITDA
$7.16M
Free Cash Flow
$-12.62M
Operating Cash Flow
$-12.62M
Shares Outstanding
56.41M
Gross Margin
-
Payout Ratio
-
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue -----------3.81M67.00K172.00K696.00K169.00K51.00K38.00K-2.11M708.00K247.00K896.00K1.08M223.00K269.00K218.00K140.00K114.00K65.00K-5.11M11.80M3.05M39.66M258.00K
Cost of Revenue ------------------------------------
Gross Profit ------------------------------------
Operating Expenses -------------------------------19.67M14.16M10.38M8.25M7.80M
Operating Income ---7.91M--7.60M-10.16M-9.97M--10.82M-9.97M-10.94M-5.70M-13.65M-17.98M--22.82M-18.48M-19.02M-19.40M-18.54M-22.52M-30.21M-26.08M-11.83M-14.23M-12.89M-1.93M-13.98M-19.06M-18.59M--14.56M-2.36M-7.33M31.41M-7.54M
EBITDA --------------------------------14.56M-2.36M-7.33M31.41M-7.54M
Interest Expense ------------------------------------
Pretax Income --------------------------------13.87M-1.70M-7.38M31.78M-7.20M
Tax Provision ------------------------------290.00K--0261.00K-
Net Income -5.91M-6.06M-6.32M-7.21M-5.88M-9.17M-9.84M-13.86M-10.64M-9.96M-10.46M-5.10M-13.20M-17.70M--23.30M-17.50M-18.90M-19.40M-18.60M-22.50M-32.80M-28.70M-11.70M-13.30M-11.90M-3.20M-12.67M-17.86M-17.15M--13.87M-1.70M-7.38M31.52M-7.20M
Diluted EPS --------------------0.63-0.70-1.01-0.87-0.33-0.25-0.23-0.06-0.24-0.33-0.32--0.25-0.03-0.130.53-0.13
R&D Expense --6.00M-6.00M7.46M6.91M-8.93M7.37M8.46M9.53M12.03M18.50M-20.44M15.66M17.71M18.40M14.46M14.44M16.97M8.17M7.36M8.98M9.51M16.39M17.33M23.73M26.86M-13.61M10.67M8.60M-2.91M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue -335.00K1.98M3.97M4.74M258.00K-48.58M96.73M27.40M59.62M
Cost of Revenue -----------
Gross Profit -----------
Operating Expenses -------79.15M69.95M99.88M52.46M
Operating Income -13.33M-33.22M-41.73M-42.81M-63.22M-79.11M--30.57M26.79M-72.48M7.16M
EBITDA --------42.94M27.15M-72.48M7.16M
Interest Expense ------1.94M2.60M0--
Pretax Income --------46.41M25.40M-68.57M8.83M
Tax Provision -------02.60M0261.00K
Net Income -10.15M-25.49M-38.74M-41.70M-60.90M-78.30M--46.41M22.81M-68.57M8.57M
Diluted EPS --------1.230.43-1.270.15
R&D Expense 11.12M26.33M32.87M33.88M65.78M67.00M64.53M47.59M51.44M96.76M38.47M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --13.77M93.48M129.01M106.10M153.45M-124.80M182.39M110.54M68.92M
Current Assets --------113.57M131.21M107.28M67.29M
Cash & Equivalents 256.00K5.69M10.31M87.29M34.08M29.73M85.21M-109.11M76.33M52.89M40.27M
Inventory ------------
Receivables --------1.08M50.70M52.48M25.39M
Total Liabilities --7.41M8.52M13.15M31.53M21.41M-48.87M75.50M64.42M9.90M
Current Liabilities --6.92M8.16M12.32M26.66M14.34M-21.65M37.15M49.07M8.87M
Long Term Debt ------------
Total Debt --------6.65M5.54M4.30M2.90M
Total Equity -6.11M-18.55M-45.44M84.60M115.50M74.57M132.04M-75.93M106.89M46.12M59.02M
Shares Outstanding --------52.46M53.00M54.59M56.41M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow --28.96M-39.11M-39.62M-50.02M-85.87M--7.73M-32.99M-23.44M-12.62M
Investing Cash Flow --830.00K-27.00K-83.16M29.53M10.47M7.67M33.81M0--
Financing Cash Flow -34.41M116.11M69.52M16.14M130.88M84.05M-29.55M221.00K0-
Capital Expenditure -232.00K-830.00K-27.00K-2.44M-314.00K-157.00K-----
Free Cash Flow --29.79M-39.14M-42.06M-50.33M-86.03M--7.73M-32.99M-23.44M-12.62M
Net Change in Cash --------3.48M-32.77M-23.44M-12.62M

Ratios (Annual)

Figures in %.

Metric Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -----------
Operating Margin % --9,916.7%-2,108.6%-1,079.3%-1,333.1%-30,664.0%--62.9%27.7%-264.6%12.0%
Net Margin % --7,609.3%-1,957.7%-1,051.4%-1,284.3%-30,348.8%--95.5%23.6%-250.3%14.4%
ROE % 54.7%56.1%-45.8%-36.1%-81.7%-59.3%--61.1%21.3%-148.7%14.5%
ROCE % --484.7%-48.9%-36.7%-79.6%-56.9%--29.6%18.4%-117.9%11.9%

Shareholding Pattern

Insiders
22.46%
Institutions
16.22%
Public Float
20.92%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for SPRO

Google News ue, 04 Aug 2026

Spero Therapeutics to discuss drug pipeline on Aug. 12 - Stock Titan

<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxPT0FUWVFQOHVCTUlydXRtdkNGUUg3aFpBa2h2ZldfSnZoSGFpRThKUl8yV1BQNXE0YXhjWmUtUlU1VmYteGVoNXNFR014emxrUkNVOVpOaGdQV2JSc0dNTlVjRzFYZ2RmelpkUU1JLU9xenZ4eUdvQzZ6d1gwXzNqTnozSmZLcWVGWkhoOT…

Google News Fri, 26 Jun 2026

$SPRO stock is up 11% today. Here's what we see in our data. - Quiver Quantitative

<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxOdEpRa0Q3d3I1ckdGMnk0WmRadWYtTExoSXljUHdTWDV3bEd1bEdobDB5ejRCdFpkNEhIaENTQl83cThtYWtQVERnLXM3ZmtIOFNQMXFCZmswSjBGT0cxRXpGMm11UmN4RGMwVEl6R21MTG15UkRxb2drNFhteUNlOTdGYU43LXJ0RkZyej…

Google News hu, 18 Jun 2026

Spero Shares Jump After FDA Clears First Oral Carbapenem Antibiotic for U.S. Market (SPRO) - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxQSzVIUmVVLWZQTGFOaVhxNnVBMWhHSGp1OHA3aGEyTERrR1NUYWR2YlZMdW1EaURQdXkwUjlLVFhDVjl6NWxsblloMElkQlJOdTA2WWNRV1BxNW1TSXdqTjJuVVZiZWFzdW9PQU4tUE5zR0x1T1BfQXZlck5pWkZWTm1aT0tyamlsbllnVE…

Google News hu, 25 Jun 2026

SPRO Forecast — Price Target — Prediction for 2027 - TradingView

<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE1pT0dnbllkeS1HMVprRzJQS3ZUUFhRd2RuRXFfSlcxQkJmYVk1Y2NCV1dCWUltSkhTdnVnT0MxTUxZc2dKVElXMUVvUU5WYVdncGcxUkJWMGl3STMzTWtoeDlQbWFOZWs2YUlOYS1Ka0lOdkRqVlAzWkRn?oc=5" target="_blank">SPR…

Google News hu, 18 Jun 2026

Spero Therapeutics stock surges on FDA approval of Utebzi - Investing.com

<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxPRUw1WjNvcnp5dEphNEc4ZWRZNnZPbXd1NzdFbnpjSVJhbFVucXV0YlpxSTQ3OG14WGlnRFhGVXVtbU9qSllIMWQ4NElTTTNsUlZoZDItaDlaZW9EVVZHcHphaWZUakxPenZydnh6QXBGY1pYUFZXUDNYUC13bFhwaWlOd2xTaEtHZnZpM1…

Google News Wed, 17 Jun 2026

SPRO Stock Slumps As Volatility Grips Small-Cap Biotech - timothysykes.com

<a href="https://news.google.com/rss/articles/CBMif0FVX3lxTE9PNG1kdWFfb2RsTl9mZ0hXODNxbmJ4ZWU0cGdvLWgxdlhlOXE0UWpWc1BmOHNmaVotQ1EyOVJKY3B1T3BFdVZ3d2ZlY0wwaExHS1BsQS1SWEdFWElPc3JZYlBmSjNidHQ1d293Snk5dmZyOXRPWUZFZkpsczVGSGM?oc=5" target="_bla…

SPRO — Frequently Asked Questions

What is the current share price of SPRO?

As of 2026-08-05 17:25 PDT, SPRO trades at $1.26 on NASDAQ/NYSE. Its 52-week range is $1.15 to $2.98.

What is the market capitalisation of SPRO?

SPRO has a market capitalisation of $71.08M on NASDAQ/NYSE.

What is the P/E ratio of SPRO?

SPRO trades at a trailing price-to-earnings (P/E) ratio of 8.40. Its price-to-book (P/B) ratio is 1.20.

What is the return on equity (ROE) of SPRO?

SPRO has a return on equity (ROE) of 14.52%. Its return on capital employed (ROCE) is 11.92%.

Is SPRO a good stock to buy?

This page provides a data-driven analysis of SPRO, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space